CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Advance Clinical-Stage Bladder Cancer Pipeline by Seini Moimoi | Aug 2, 2023 | Uncategorized
LEXEO Therapeutics Announces Completion of First Cohort and Dosing in Second Cohort in SUNRISE-FA, a Phase 1/2 Clinical Trial of LX2006 for the Treatment of Friedreich’s Ataxia Cardiomyopathy by Seini Moimoi | Jun 13, 2023 | Uncategorized
WelbeHealth Continues Los Angeles Expansion With Opening of New PACE Centers in Rosemead and North Hollywood by Seini Moimoi | Jun 8, 2023 | Uncategorized
Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update by Seini Moimoi | May 16, 2022 | Uncategorized, Portfolio News
89bio Initiates Phase 2b ENLIVEN Trial of BIO89-100 for the Treatment of NASH by Seini Moimoi | Jun 10, 2021 | Uncategorized
Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 Deficiency by Seini Moimoi | Jun 9, 2021 | Uncategorized
